Study M1012
Study name | Li B 2022 |
Title | Engineered 5-HT producing gut probiotic improves gastrointestinal motility and behavior disorder |
Overall design | In this study, the authors genetically engineered the probiotic Escherichia coli Nissle 1917 (EcN-5-HT) for synthesizing 5-HT in situ. The oral delivered engineered probiotic showed therapeutic activities that efficiently alleviated constipation symptoms and related behaviour disorders. C57BL/6J mice were divided into the following 3 groups (n = 8 in each group): (1) control group, (2) loperamide group, and (3) loperamide + probiotic group (loperamide plus Escherichia coli Nissle 1917 treatment). The loperamide-induced constipation model was established by 7 days of twice-daily intraperitoneal administration of loperamide hydrochloride (8 mg/kg). After that, EcN-5-HT (1x10^9 CFU) was given through gavage every two days to the mice for 14 days. The levels of 5-HT in colon and serum were then detected by UPLC-MS/MS (n = 8/group). |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Mouse; C57BL/6J mouse; |
Categories of depression | Animal model; Other animal model; Other animal model; |
Criteria for depression | Forced swimming test, tail suspension test |
Sample size | 24 |
Tissue | Peripheral; Gut; Colon; Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: AB Sciex 4500 UPLC-MS/MS system (AB Sciex, USA); |
PMID | |
DOI | |
Citation | Li B, Li M, Luo Y, et al. Engineered 5-HT producing gut probiotic improves gastrointestinal motility and behavior disorder. Front Cell Infect Microbiol. 2022 Oct 20;12:1013952. |
Metabolite |
